Laura E Miller1, Matthew M Laughon2, Reese H Clark3, Kanecia O Zimmerman1,4, Christoph P Hornik1,4, Samia Aleem1,4, P Brian Smith1,4, Rachel G Greenberg5,6. 1. Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA. 2. Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 3. MEDNAX Center for Research, Education, Quality, and Safety, Sunrise, FL, USA. 4. Duke Clinical Research Institute, Durham, NC, USA. 5. Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA. rachel.greenberg@duke.edu. 6. Duke Clinical Research Institute, Durham, NC, USA. rachel.greenberg@duke.edu.
Abstract
OBJECTIVE: The management of early hypotension in extremely low gestational age neonates (ELGANs) varies greatly between centers. The objective of this study was to provide updated data on the use of vasoactive medications in ELGANs during the first postnatal week. STUDY DESIGN: We identified ELGANs (22-27 weeks gestational age) cared for at Pediatrix neonatal intensive care units from 2009 to 2018. We evaluated the frequency of exposure to vasoactive medications by gestational age, and compared use of vasoactive medications between two epochs (2009-2013 and 2014-2018). RESULTS: A total of 10,070/34,234 (29%) ELGANs received ≥1 vasoactive medication. Dopamine was the most frequently used vasoactive medication. The majority (83%) of treated ELGANs initiated therapy on postnatal days 0-1. Overall use of vasoactive medications was slightly lower in 2014-2018 than 2009-2013 (28 vs 31%, p < 0.001). CONCLUSION: A substantial proportion of ELGANs were exposed to vasoactive medications during the first postnatal week.
OBJECTIVE: The management of early hypotension in extremely low gestational age neonates (ELGANs) varies greatly between centers. The objective of this study was to provide updated data on the use of vasoactive medications in ELGANs during the first postnatal week. STUDY DESIGN: We identified ELGANs (22-27 weeks gestational age) cared for at Pediatrix neonatal intensive care units from 2009 to 2018. We evaluated the frequency of exposure to vasoactive medications by gestational age, and compared use of vasoactive medications between two epochs (2009-2013 and 2014-2018). RESULTS: A total of 10,070/34,234 (29%) ELGANs received ≥1 vasoactive medication. Dopamine was the most frequently used vasoactive medication. The majority (83%) of treated ELGANs initiated therapy on postnatal days 0-1. Overall use of vasoactive medications was slightly lower in 2014-2018 than 2009-2013 (28 vs 31%, p < 0.001). CONCLUSION: A substantial proportion of ELGANs were exposed to vasoactive medications during the first postnatal week.
Authors: Jonathan M Fanaroff; Deanne E Wilson-Costello; Nancy S Newman; Michelle M Montpetite; Avroy A Fanaroff Journal: Pediatrics Date: 2006-04 Impact factor: 7.124
Authors: Margrete Larsen Burns; Hans Jørgen Stensvold; Kari Risnes; Hans Jørgen Guthe; Henriette Astrup; S Marianne Nordhov; Terje Reidar Selberg; Arild Rønnestad; Astri Maria Lang Journal: Pediatr Crit Care Med Date: 2016-10 Impact factor: 3.624
Authors: Beau Batton; Lei Li; Nancy S Newman; Abhik Das; Kristi L Watterberg; Bradley A Yoder; Roger G Faix; Matthew M Laughon; Barbara J Stoll; Rosemary D Higgins; Michele C Walsh Journal: Arch Dis Child Fetal Neonatal Ed Date: 2015-11-13 Impact factor: 5.747